Tilray has been growing its business outside of just cannabis over the years. Surprisingly, it is now one of the largest craft brewers in the U.S. Stronger margins in the alcohol business are helping Tilray's financials.
Tilray's craft beer acquisitions are driving sales higher. Management expects continued revenue growth in fiscal 2025.
Tilray reported strong revenue growth in FQ4, but most of it was not organic, mainly driven by acquisitions in the Beverage Alcohol sector. Despite acquisitions, non-beverage segments saw a decline in non-wholesale sales, raising concerns about the company's ability to manage a far-flung business effectively. The company forecast limited organic growth for Tilray in FY25, making TLRY stock expensive trading at 17x adjusted EBITDA and a history of missing financial targets.
Canadian cannabis and beverage firm Tilray beat top and bottom street estimates for its fiscal Q4 period. The company has made strong progress on reducing its large debt pile. While progress is being made, shareholders are facing significant dilution over time.
Tilray Brands, Inc. (NASDAQ:TLRY ) Q4 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Robert Moskow - TD Cowen Andrew Carter - Stifel Aaron Grey - Alliance Global Partners Owen Bennett - Jefferies Frederico Gomes - ATB Capital Markets Conference Call Participants Berrin Noorata - Chief Corporate Affairs and Communications Officer Irwin Simon - Chairman and CEO Carl Merton - CFO Denise Faltischek - Chief Strategy Officer and Head of International Operator Hello, and thank you for joining today's conference call to discuss Tilray Brands' Financial Results for the Fourth Quarter and Fiscal Year 2024 ended May 31, 2024. [Operator Instructions] I'll now turn the call over to Ms.
The headline numbers for Tilray Brands (TLRY) give insight into how the company performed in the quarter ended May 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Tilray Brands, Inc. (TLRY) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to break-even earnings per share a year ago.
Tilray (NASDAQ: TLRY ) stock is on the move Monday as investors in the cannabis company react to it securing a trading license in Germany for its Aphria RX subsidiary. With this trading license, Aphria RX is now able to sell and distribute medical cannabis products to a wide range of locations.
Tilray Brands (NASDAQ: TLRY) stock price will be in the spotlight this week as it publishes its second-quarter financial results. These numbers will come at a time when it is hovering near its year-to-date low of $1.60.
Tilray's (TLRY) product innovation, spanning medical cannabis formats, THC-infused beverages and pharmaceutical-grade medicines, enhances its ability to capture new market segments globally.
Tilray Brands, Inc. (TLRY) closed at $1.89 in the latest trading session, marking a -1.56% move from the prior day.
Tilray Brands (NASDAQ: TLRY ) stock jumped almost 3% early on July 22 after it got good news from Germany. The marijuana and beer company received a cultivation license from German authorities.